EPICS Therapeutics SA, a recently launched spin-off of ULB (April 2018) focused on discovery and development of innovative small molecules anti-cancer drugs acting on RNA epigenetics, today announced it has entered into a Business Transfer Agreement with Ogeda SA. On Dec 31st 2018, part of the Ogeda assets, including research stage programs and the EuroscreenFast Business Services Unit will be acquired by EPICS. The financial details of the transaction are not disclosed. In parallel of this acquisition, EPICS will also raise €14.2 Million ($16.1 Million) to fund further developments. Discover the press release here.